| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ENTPD8 |
| Uniprot No | Q5MY95 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-458aa |
| 氨基酸序列 | MGLSRKEQVFLALLGASGVSGLTALILLLVEATSVLLPTDIKFGIVFDAGSSHTSLFLYQWLANKENGTGVVSQALACQVEGPGISSYTSNAAQAGESLQGCLEEALVLIPEAQHRKTPTFLGATAGMRLLSRKNSSQARDIFAAVTQVLGRSPVDFWGAELLAGQAEGAFGWITVNYGLGTLVKYSFTGEWIQPPEEMLVGALDMGGASTQITFVPGGPILDKSTQADFRLYGSDYSVYTHSYLCFGRDQMLSRLLVGLVQSRPAALLRHPCYLSGYQTTLALGPLYESPCVHATPPLSLPQNLTVEGTGNPGACVSAIRELFNFSSCQGQEDCAFDGVYQPPLRGQFYVEASYPGQDRWLRDYCASGLYILTLLHEGYGFSEETWPSLEFRKQAGGVDIGWTLGYMLNLTGMIPADAPAQWRAESYGVWVAKVVFMVLALVAVVGAALVQLFWLQD |
| 分子量 | 77.33 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人ENTPD8蛋白的参考文献示例，内容基于现有领域知识综合概括，可能与实际文献存在差异，建议通过学术数据库进一步核实：
1. **文献名称**：*"Characterization of recombinant human ENTPD8: enzymatic properties and substrate specificity"*
**作者**：Zhang Y. et al.
**摘要**：研究报道了重组人ENTPD8蛋白在大肠杆菌系统中的表达与纯化，分析了其水解ATP、ADP等核苷酸的动力学特性，揭示了其在细胞外嘌呤代谢中的潜在作用。
2. **文献名称**：*"Structural insights into the catalytic mechanism of ENTPD8 through X-ray crystallography"*
**作者**：Lee S. & Kim J.
**摘要**：通过重组人ENTPD8蛋白的晶体结构解析，阐明了其活性位点关键氨基酸残基的功能，探讨了与其他ENTPD家族成员(如CD39/ENTPD1)的结构差异。
3. **文献名称**：*"ENTPD8 deficiency exacerbates colitis in mice via dysregulated extracellular ATP signaling"*
**作者**：Müller C.E. et al.
**摘要**：利用重组ENTPD8蛋白进行体外功能验证，发现其可通过水解促炎性ATP分子缓解肠道炎症反应，提示其在炎症性肠病治疗中的应用潜力。
4. **文献名称**：*"Recombinant ENTPD8 suppresses hepatic fibrosis by modulating purinergic signaling in stellate cells"*
**作者**：Wang H. et al.
**摘要**：研究发现重组ENTPD8蛋白通过调节肝星状细胞外ATP/ADP水平，抑制TGF-β通路活化，为肝纤维化提供了新的干预靶点。
---
**备注**：上述文献为示例性概括，实际研究请参考PubMed、Web of Science等数据库，以具体实验方向为关键词检索最新成果。
**Background of Recombinant Human ENTPD8 Protein**
Recombinant human ENTPD8 (ectonucleoside triphosphate diphosphohydrolase 8) is a purified, engineered form of the ENTPD8 enzyme, belonging to the ectonucleoside triphosphate diphosphohydrolase (ENTPDase) family. ENTPD8 is a transmembrane glycoprotein that hydrolyzes extracellular nucleotides, primarily ATP and ADP, to regulate purinergic signaling pathways. It plays a role in modulating inflammation, immune responses, and tissue homeostasis, with reported expression in tissues such as the intestine, liver, and immune cells.
The recombinant protein is typically produced via heterologous expression systems (e.g., mammalian or bacterial cells) to ensure high purity and bioactivity. Its structure includes conserved apyrase regions critical for enzymatic function. Research focuses on its involvement in metabolic disorders, inflammatory diseases (e.g., colitis), and cancer, where dysregulated nucleotide signaling contributes to pathogenesis. Recombinant ENTPD8 is utilized in vitro and in vivo to study its enzymatic kinetics, receptor interactions, and therapeutic potential. Recent studies also explore its role in gut microbiota modulation and as a biomarker for certain malignancies. Its development aids drug discovery, particularly in targeting purinergic pathways for anti-inflammatory or anti-tumor therapies.
×
